{"id":"W3088817799","doi":"10.1016/j.annonc.2020.08.419","title":"317P Updated results from the Canadian sub-population of the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Novartis (Canada); Ottawa Hospital; BC Cancer Agency; Sunnybrook Health Science Centre; McGill University; Jewish General Hospital; University of Alberta; Grand River Hospital","funders":"Medac; Eisai; Amgen; Pfizer; Genomic Health; Genentech; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Neutropenia; Internal medicine; Breast cancer; Letrozole; Population; Febrile neutropenia; Interim analysis; Chemotherapy regimen; Progression-free survival; Cancer; Surgery; Chemotherapy; Clinical trial; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003015341,0.001238124,0.001741902,0.0009774207,0.0009806008,0.002253768,0.001428844,0.001069446,0.02079364],"category_scores_gemma":[0.008011714,0.0005209928,0.002744564,0.00319727,0.0003862618,0.0007252535,0.0008613212,0.001680839,0.002791969],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.008397593,"about_ca_system_score_gemma":0.02027362,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.5989306,"about_ca_topic_score_gemma":0.8198357,"domain_scores_codex":[0.9978625,0.0004819733,0.000109146,0.000195798,0.0009763048,0.00037422],"domain_scores_gemma":[0.9965119,0.0006123388,0.0004085086,0.0002770132,0.00173196,0.000458231],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.06240412,0.0002263671,0.01600417,0.001875426,0.00602365,0.0001876697,0.000112693,0.001996796,0.0009220407,0.0009128478,0.788672,0.1206622],"study_design_scores_gemma":[0.1014773,0.002479936,0.2785095,0.001696146,0.02591674,0.0005576063,0.0002747389,0.002132156,0.001338496,0.00423196,0.5811104,0.000275015],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"dataset","genre_gemma":"empirical","genre_scores_codex":[0.06739512,0.02785887,0.001951516,0.01346265,0.002462087,0.002519835,0.8157796,0.0005437163,0.06802659],"genre_scores_gemma":[0.2965935,0.01938354,0.005029517,0.0155084,0.002035962,0.003662854,0.5976939,0.0005836545,0.0595087],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.5989306,"threshold_uncertainty_score":0.8068628,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1034470489164256,"score_gpt":0.4071122338212833,"score_spread":0.3036651849048577,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}